Milano, Lombardia, Italia
4720 follower
Oltre 500 collegamenti
4720 follower
Oltre 500 collegamenti
Informazioni
International Executive and Venture Professional with successful general management…
Articoli di Edoardo
-
Europe’s Biotech Moment: When Super Science Meets Smart Capital
Europe’s Biotech Moment: When Super Science Meets Smart Capital
The future of biotech is being written in Europe right now. Not with a single stroke, but with a symphony of bold…
3 commenti -
Why Spain Wins the Biotech “Valley of Death” — and Who Will Step Up in Italy?
Why Spain Wins the Biotech “Valley of Death” — and Who Will Step Up in Italy?
People often ask: how has Spain managed to build such an effective life sciences ecosystem—one that maximizes the value…
4 commenti -
Biotech is blooming in Italy
Biotech is blooming in Italy
Italy is blooming in biotech, with a slew of initiatives growing from seed stage to series A. The environment has…
2 commenti
Attività
4720 follower
-
Edoardo Negroni ha condiviso questo elementoCan Europe compete with China and the US in biotech? The answer is YES—and the numbers prove it: €116M Series A rounds, €165M venture labs, 130+ startups launched. From BII’s model and Panakès’ execution to Biovelocita, Argobio, HTGF, and Fundació La Caixa, the continent is shelling out biotech champions at scale. Full analysis in my latest article. #BiotechRevolution #EuropeRising #InnovationEurope’s Biotech Moment: When Super Science Meets Smart CapitalEurope’s Biotech Moment: When Super Science Meets Smart Capital
-
Edoardo Negroni ha condiviso questo elementoThe first funded initiative to scale up incubation in Europe in early stage biotechEdoardo Negroni ha condiviso questo elemento🚨 BREAKING NEWS: The Novo Nordisk Foundation is funding CardioMetabolic Bridge, a six-year, DKK450m (€60.2m) European incubator network to help university discoveries in obesity, diabetes and cardiovascular disease become drug development projects. 🤔 Why it matters: Europe produces strong academic science, but many promising discoveries stall before they are validated, financed or developed into medicines. This programme aims to close that gap by giving researchers the funding, lab access, mentoring and drug discovery support needed to make projects attractive to investors, pharma companies or spinout teams. ⏳ Backstory: The initiative builds on the foundation’s broader plan to expand the BioInnovation Institute as a European life sciences innovation platform. In January, the Novo Nordisk Foundation committed up to DKK5.5bn (€736m) to BII for 2026–2035 to help turn more European science into companies, jobs and technologies. 🌍 Big picture: Cardiometabolic disease has become one of pharma’s most important fields, driven by the success of GLP-1 drugs such as Ozempic and Wegovy and the growing health burden of obesity, type 2 diabetes and cardiovascular complications. CardioMetabolic Bridge gives the foundation’s innovation strategy a sharper therapeutic focus. 🔎 Zoom in: The first hub will open in London in this month, followed by sites in Italy and Germany later in the year. BII will manage the network, drawing on its experience supporting more than 130 companies. The programme is expected to support about 30 academic projects over six years. ✅ Don’t miss the next biotech story from European Biotechnology Magazine Subscribe here: https://lnkd.in/e5KjDRmt
-
Edoardo Negroni ha diffuso questo postEdoardo Negroni ha diffuso questo postFor many years, #RAS and #MYC shared a common label: "undruggable." Today, the success of RAS-targeted therapies stands as one of the most remarkable achievements in cancer drug discovery. It is a testament to what can happen when scientists refuse to accept that a difficult problem is an impossible one. That is why I found a recent Nature News & Views article particularly inspiring: looking beyond the progress achieved with RAS, the authors point to other challenging targets that may define the next generation of breakthroughs in oncology. Among them is MYC. As someone who has dedicated much of her scientific career to understanding and targeting MYC, I feel deeply honored to see this field recognized as a promising frontier and Peptomyc mentioned among the key players helping to move it forward. For decades, MYC has represented both one of the greatest challenges and one of the greatest opportunities in cancer research. The growing belief that MYC can be effectively targeted gives hope not only to researchers, but most importantly to patients waiting for new therapeutic options. The story of RAS reminds us that "undruggable" is not a scientific law. It is a challenge to be overcome. I am grateful to all the scientists, clinicians, patients, investors, and collaborators who continue to push these boundaries every day. The journey continues. #CancerResearch #Oncology #MYC #RAS #Biotech #DrugDiscovery https://lnkd.in/e2KMZnJALandmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatmentsLandmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments
-
Edoardo Negroni ha condiviso questo elementoEurope just got its first standalone, philanthropy-funded institute dedicated exclusively to immunology. We should want more of them. Last week, the "la Caixa" Foundation inaugurated the CaixaResearch Institute in Barcelona. What makes it genuinely different is the architecture of the model: 🔬 Focus — Immunology as a cross-cutting biological lens across oncology, neurodegeneration, infection, and inflammation simultaneously. A deliberate break from the traditional indication-first paradigm. 🏛️ Governance — A fully standalone entity with its own Scientific Council — led by oncologist Josep Tabernero — insulated from short-term grant cycles and built for integrative, multi-disciplinary science. 💰 Funding — €100M construction + €100M operational, co-financed by the European Investment Bank. The patient, independent capital that translational immunology actually needs. The honest question: why is this model so rare in Europe? Biology is integrated. Our research infrastructure largely is not. The same immune mechanisms connecting autoimmunity, tumour evasion, neuroinflammation, and rare diseases are studied in separate silos. Indication-siloed institutes produce indication-siloed science — at the cost of the lateral discoveries that most often become transformative therapies. Checkpoint immunotherapy, CAR-T, cytokine blockade all came from fundamental immune biology questions, not indication-specific ones. More institutes like this across Europe would compound returns in 3 ways: → More discoveries — mechanistic insights seeding therapeutics across multiple disease areas at once. → Integrated skills — immunologists, computational biologists, engineers, and clinicians building the cross-disciplinary fluency that complex diseases demand. → Excellence that retains talent — giving Europe's best researchers a reason to stay, rather than move to La Jolla, Boston, or Basel. CaixaResearch is a proof of concept. Now Europe needs the will to replicate it. 🔗 https://lnkd.in/dXQvSgSp #Immunology #EuropeanLifeSciences #BiomedicalResearch #PhilanthropyInScience #TranslationalMedicine #DrugDiscovery #Oncology #Neuroscience #OpenInnovation #EuropeanBiotech #SciencePolicy #BiotechSnap #BioSpace #CaixaResearchInstitute #LifeSciencesThe ”la Caixa” Foundation inaugurates the CaixaResearch Institute, the first research centre specialising in immunology in Spain and Portugal | "la Caixa" FoundationThe ”la Caixa” Foundation inaugurates the CaixaResearch Institute, the first research centre specialising in immunology in Spain and Portugal | "la Caixa" Foundation
-
Edoardo Negroni ha condiviso questo elementoEurope has the science. The question is whether we have the architecture to scale it. Strong research clusters exist across the continent — immuno-oncology in the Netherlands, rare diseases in France and Italy, genomics in the UK, infectious diseases in Scandinavia. The talent is there. What we are still building is the connective tissue. The European Life Sciences Coalition (ELSC) launch — members managing over €24B in life sciences assets — is a strong signal, but also an honest diagnosis: fragmented markets, nationally bound funds, and a Series B cliff where too many startups turn to the US to survive. Public anchors like KfW, Bpifrance, the EIF, CDP Venture Capital, the British Business Bank, ISIF, Invest-NL, Vækstfonden, CDTI and Tesi are indispensable. Private champions like Novo Holdings, Jeito Capital, Sofinnova and Forbion are proving large-scale European capital is achievable. Yet the architecture remains incomplete. Scale-up investment must operate at a European level. Pan-European capital that follows the best opportunities continent-wide, bridges early- and late-stage investors, and complements EU Inc. reforms will keep our breakthroughs at home. Jeito II at €1B is a bellwether, not a ceiling. Full piece here → https://lnkd.in/dJqf89Yn Honoured to be featured alongside Naveed Siddiqi (Novo Holdings) — a model of patient, mission-aligned capital that builds ecosystem confidence, not just portfolios. Thank you Jennifer Smith-Parker for the sharp piece. #EuropeanBiotech #LifeSciences #VentureCapital #ELSC #OpenInnovation #Biopharma #EIF #Bpifrance #KfW #CDPVentureCapital #BritishBusinessBank #ISIF #InvestNL #Vækstfonden #CDTI #Tesi #NovoHoldings #SofinnovaPartners #Forbion #JeitoCapital #EUInc #ScaleUp #BiotechEurope #HealthcareInnovation #PatientCapitalCan Europe turn world-class science into world-class scale?Can Europe turn world-class science into world-class scale?
-
Edoardo Negroni ha condiviso questo elementoEuropean biotech has a translation problem. The science is world-class. The funding infrastructure at early stage is not. J.P. Morgan's Q1 2026 data is unambiguous: Seed and Series A deal count is heading toward its lowest level since pre-COVID. Capital is concentrating at Phase II and beyond. First-time financings are vanishing. In Europe, this is not a cycle. It is a structural gap. 66 out of 67 EU biotechs that went public in the last six years did so outside the EU. Southern Europe — despite strong academic pipelines and Spain leading the continent in clinical trials — remains systematically underfunded by private capital. Three interventions are overdue: → Public capital must go earlier. EIC, EIF and national funds should commit through end-of-Phase-II. Private capital will not fill this gap alone. → Venture studios and incubators should become standard TTO output. Not more spinouts on paper — more fundable companies built with discipline from day one. → Selection must be ferocious. More public money does not mean undiscriminating money. The science filter has to be rigorous. Europe is not short of science. It is short of the infrastructure to turn science into companies. What early-stage models are working in your ecosystem? https://lnkd.in/daxezeV4 #EuropeanBiotech #EarlyStage #VentureCapital #LifeSciences #OpenInnovation #Biopharma #VentureStudio #TTO #EIC #EIF #Innovation #DrugDiscovery #Biotech #ELSC #PublicPrivatePartnershipQ1 2026 Biopharma Licensing and Venture Report April 2026Q1 2026 Biopharma Licensing and Venture Report April 2026
-
Edoardo Negroni ha condiviso questo elementoAurorA Science is doubling down on Peptomyc. This €5M round is the catalyst for OMO-103—the first clinically validated MYC inhibitor—to finalize clinical data, achieve manufacturing readiness and to generate new data to support upcoming strategic partnerships. The objective is to scale this breakthrough for global impact for the benefit of the patients. #PharmaPartnering #Biotech #LifeSciences #VentureCapital #Oncology #PancreaticCancer #DrugDevelopment #ClinicalTrials #Biotechnology #StrategicPartnerships #BusinessDevelopment #HealthTech #PrecisionMedicine #MYC #Innovation #LifeScienceVC #CancerResearch #TechTransfer #PharmaIndustry #EuropeanBiotechEdoardo Negroni ha condiviso questo elementoWe are pleased to announce that Peptomyc has closed a €5 million equity financing to advance OMO-103 toward the next stage of development, as the company looks ahead to several upcoming clinical readouts. The round was led by Alta Life Sciences and AurorA Science, with participation from the EIC Fund, part of the European Innovation Council, Laudecum, and CDTI Innovación through its Innvierte program. This milestone reflects continued confidence in Peptomyc’s innovative approach and strengthens its path toward delivering new therapeutic options in oncology. We look forward to the next phase of clinical progress and strategic partnerships. https://shorturl.at/59hD8Peptomyc Closes €5 Million Equity Financing to Advance OMO-103 Toward the Next Stage of DevelopmentPeptomyc Closes €5 Million Equity Financing to Advance OMO-103 Toward the Next Stage of Development
-
Edoardo Negroni ha condiviso questo elementoWhy Spain Wins the Biotech “Valley of Death” — and Who Will Step Up in Italy?Why Spain Wins the Biotech “Valley of Death” — and Who Will Step Up in Italy?Why Spain Wins the Biotech “Valley of Death” — and Who Will Step Up in Italy?
-
Edoardo Negroni ha condiviso questo elementoPfizer Ignite is closing its doors—but others are betting big on early-stage innovation When a tier-one pharma winds down an open innovation program, it signals something worth watching. Pfizer's decision to close Ignite—designed to de-risk early-stage biotech through access to labs, expertise and strategic guidance—removes a valuable non-dilutive pathway for innovators at precisely the moment when early-stage capital is tight. But the ecosystem is responding differently elsewhere. Novo Nordisk Foundation (through NovoSeeds, and NovoHoldings), Eli Lilly and Company, Roche, Amgen, and Chiesi Group, are, among others, expanding their commitment to external innovation ecosystems. They understand something fundamental: most breakthrough science originates outside pharma walls—in academia, research institutes, and startups. Since 2018, more than 70% of new molecular entity revenues have come from externally sourced products, according to many sources, such as for instance McKinsey & Company in a report of June 2025. Here's what makes the difference: pharma innovation systems, with entrepreneurs in residence (EIR) and early-stage VC funds acting as connectors, achieve higher efficacy with academia, startups, and investor networks, to de-risk assets well before Seed and Series A by aligning technology with unmet medical needs and pharma strategic priorities. That pre-investment validation is what early-stage VCs actually need to move forward with conviction. For founders and early-stage investors: pharma players betting on innovation ecosystems aren't just writing cheques. They're validating science ar inception stage, de-risking platforms, and creating pathways to partnership. Closing programs like Ignite isn't cost efficiency. It is stepping back from the very ecosystem that fills tomorrow's pipeline. Innovation is not an option for pharma. It is a matter of existence. https://lnkd.in/dYfTpBpQ #OpenInnovation #EarlyStageVC #BiotechInnovation #PharmaBD #NovoNordisk #CorporateVenture #EntrepreneurInResidence #LifeSciences #DrugDiscovery #StrategicPartnering #InnovationEcosystem #Entrepreneurship #DeRiskingPfizer Ignite, designed to accelerate promising biotech therapies, fizzles outPfizer Ignite, designed to accelerate promising biotech therapies, fizzles out
-
Edoardo Negroni ha consigliato questo elementoEdoardo Negroni ha consigliato questo elementoBuone notizie sul fronte delle malattie rare. ITALFARMACO S.P.A. ha siglato con la giapponese JCR Pharmaceuticals un accordo di licenza esclusiva per sviluppare e commercializzare negli Stati Uniti, in Europa e in America Latina la terapia sperimentale per la #sindromediHunter, una malattia genetica rara. Terapia già approvata in Giappone nel 2021. Come ricordano il CEO della multinazionale italiana Francesco Di Marco, e il vicepresidente Antonio Nardi, l'intesa rafforza la collaborazione avviata a dicembre scorso con l’accordo per la commercializzazione in Giappone di #givinostat per la distrofia muscolare di Duchenne. #malattierare #ricercafarmaceutica #terapiaenzimatica Paolo Bettica Andrea Ballerini Elisabetta Verardo Paola Cinquanta Carla Benedetto Monica Magri chiara moroniItalfarmaco, accordo con JCR per sviluppo e commercializzazione terapia per la Sindrome di HunterItalfarmaco, accordo con JCR per sviluppo e commercializzazione terapia per la Sindrome di Hunter
-
Edoardo Negroni ha aggiunto una reazioneEdoardo Negroni ha aggiunto una reazione📣 I’m thrilled to share that I am starting a new chapter in my career! After an intense and exciting period of 8 years at MENARINI Group, it is time for me to embark on a new journey. A big thank you to all the colleagues and friends I've worked with during this time! 🆕 Today I will be joining Lupin as Business Development Director, Europe. In this new role I'll have the opportunity to work closely with pharma, biotechs and investors to strengthen and expand the portfolio across European markets. Thank you to everyone who has supported, guided me along the way. I feel incredibly excited and grateful for this new adventure! 🚀 #NextChapter #BusinessDevelopment #Pharma #Lupin #Career #Growth
-
Edoardo Negroni ha consigliato questo elementoEdoardo Negroni ha consigliato questo elementoThis week has been a very special one indeed. 🤩 On Tuesday, I received the official notification that I have been selected as a finalist in the Kindness in Leadership Award (CEO/Executive Category) at the inaugural Workplace Kindness Awards. So excited and gratefull for that indeed!!!! 😍 💫 This is an extraordinary recognition, one I never imagined even existed, let alone that I would be nominated for and become a finalist. I am fully convinced that #KindnessMatters. Kindness is not only compatible with high performance; it is a key enabler of it. Achieving ambitious goals becomes much easier when you are surrounded by team members, partners, and clients who genuinely embody this value. Kindness fosters trust, motivation, engagement, and collaboration, ultimately helping organizations achieve better results. I would like to sincerely thank Tracey Ivanyshyn and Fiona Stevenson for this project and amazing initiative. In my humble opinion, #KindnessAtWork is not a "nice to have"; it is a critical ingredient for sustainable success and meaningful leadership. In addition I would like to thank the ones who have help me in this nomination. I am truly honored by this recognition and grateful to everyone who has been part of my journey. #KindnessInLeadership #Leadership #WorkplaceKindness #LeadershipMatters #PeopleFirst #Gratitude After more than three decades in clinical research and leadership, I remain convinced that people never forget how you make them feel. Kindness costs nothing, but its impact can be enormous. ❤️
-
Edoardo Negroni ha consigliato questo elementoEdoardo Negroni ha consigliato questo elementoIeri sera abbiamo festeggiato 10 anni di Primo Capital con tanti amici che hanno condiviso con noi questo percorso. Passo dopo passo siamo una trentina di professionisti operanti nei principali settore del tech, molto focalizzati sul far emergere l'eccellenza Italiana. Ora lo sguardo è sui prossimi 10 anni 🎉 🎉 🎉
Esperienza e formazione
Lingue
-
English
Conoscenza madrelingua o bilingue
-
French
Conoscenza madrelingua o bilingue
-
Italian
Conoscenza madrelingua o bilingue
-
Spanish
Conoscenza professionale
-
German
Conoscenza lavorativa limitata